Want to see GB:PRTC full AI Analyst Report?
Top Page
PureTech Health
(LSE:PRTC)
Select Model
Select Model
Rating:51Neutral
Price Target:
113.00 p
▼(-7.68% Downside)
Action:Reiterated
Date:09/23/26
The score is held down primarily by weak financial performance (ongoing losses and cash burn) and bearish technicals (below key moving averages with negative MACD). This is partially offset by a constructive earnings update pointing to extended runway, lower expected burn, and meaningful portfolio milestones, while valuation inputs are unavailable and therefore not a differentiator.
Positive Factors
Capital-efficient portfolio model
The hub-and-spoke model can reduce PureTech’s direct funding burden while preserving ownership and downstream economics. Internal derisking followed by external financing may support repeated asset creation, improve capital efficiency, and diversify value creation across several therapeutic programs.
Negative Factors
Persistent operating losses
Large operating and net losses show that PureTech remains dependent on portfolio milestones, financing, or asset monetization rather than internally generated profits. Volatile and declining revenue also makes earnings less predictable, limiting the company’s ability to self-fund development.
Read all positive and negative factors
Positive Factors
Negative Factors
Capital-efficient portfolio model
The hub-and-spoke model can reduce PureTech’s direct funding burden while preserving ownership and downstream economics. Internal derisking followed by external financing may support repeated asset creation, improve capital efficiency, and diversify value creation across several therapeutic programs.
Read all positive factors
PureTech Health (PRTC) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£288.33M
Dividend YieldN/A
Average Volume (3M)656.99K
Price to Earnings (P/E)157.4
Beta (1Y)1.34
Revenue Growth-4.11%
EPS Growth-96.92%
CountryUK
Employees56
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.01
Shares Outstanding245,179,640
10 Day Avg. Volume409,708
30 Day Avg. Volume656,988
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.30
Price to Sales (P/S)85.14
P/FCF Ratio-4.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.46
Revenue Forecast (FY)£10.67M
PureTech Health Business Overview & Revenue Model
Company Description
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neu...
How the Company Makes Money
PureTech Health makes money primarily through (1) value creation and monetization of its founded entities and (2) partnering and commercialization economics from therapeutic programs. Revenue and cash inflows can come from: (a) proceeds from equit...
PureTech Health Earnings Call Summary
Earnings Call Date:Sep 22, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Apr 29, 2027
Earnings Call Sentiment Positive
The call was predominantly positive, with management highlighting major portfolio milestones, external financing, Seaport's IPO, Celea's Phase III launch, Gallop's FDA Fast Track designation, a cash runway extending at least through the end of 2028, lower expected future cash burn and a growing innovation pipeline. The main negatives were the year-to-date cash decline, higher first-half operating expenses, the material downgrade in estimated future Cobenfy proceeds, Celea's expected need for additional financing and Gallop's dependence on external financing before its Phase II trial can begin.Positive Updates
Strong Strategic Execution Across Portfolio
Management stated that PureTech made significant progress in 2026 and meaningfully executed against its refined strategy, including Seaport's NASDAQ IPO, Celea's external financing and Phase III initiation, Gallop's Fast Track designation, continued potential future Cobenfy economics, and advancement of the innovation engine.
Negative Updates
Decline in Cash Balance During the First Half
PureTech-level cash, cash equivalents and short-term investments declined to approximately $220 million at June 30, 2026, from $277.1 million at year-end 2025. On a consolidated basis, the figures were $220.1 million versus $277.3 million.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Strategic Execution Across Portfolio
Management stated that PureTech made significant progress in 2026 and meaningfully executed against its refined strategy, including Seaport's NASDAQ IPO, Celea's external financing and Phase III initiation, Gallop's Fast Track designation, continued potential future Cobenfy economics, and advancement of the innovation engine.
Read all positive updates
Company Guidance
PureTech reiterated an operational runway at least through the end of 2028, excluding inflows from potential future monetization events and assuming full deployment of the additional $70 million reserved for potential future investments in Celea; it expects go-forward cash burn, including overhead and innovation spend, to be somewhere between $30 million and $40 million a year, compared with the roughly $90 million a year cash burn when later-stage clinical programs were run internally. Gallop intends to complete external financing by the first half of next year, initiate STRIDE-MDS following receipt of external capital, and the approximately 125-patient trial is projected, on the more conservative side, to take probably somewhat under 3 years to complete, with the actual time line potentially more around 30 months or 33 months; PureTech aims to advance at least 3 opportunities to the concept stage each year, is currently running ahead of that, and expects to share additional detail in the first half of 2027.PureTech Health Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
70
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.31M | 4.76M | 4.32M | 750.00K | 2.09M | 9.98M |
| Gross Profit | 3.03M | 1.34M | 4.32M | -92.91M | -136.81M | -100.49M |
| EBITDA | -98.83M | -97.17M | 37.38M | -17.68M | -79.94M | -46.95M |
| Net Income | 474.87K | -112.04M | 53.51M | -65.70M | -50.35M | -60.56M |
Balance Sheet | ||||||
| Total Assets | 640.59M | 534.90M | 602.63M | 693.97M | 702.65M | 946.01M |
| Cash, Cash Equivalents and Short-Term Investments | 222.51M | 279.00M | 367.31M | 327.14M | 350.10M | 465.71M |
| Total Debt | 18.57M | 19.76M | 159.14M | 25.34M | 46.87M | 52.75M |
| Total Liabilities | 259.13M | 229.12M | 194.70M | 235.74M | 155.06M | 361.86M |
| Stockholders Equity | 388.24M | 312.19M | 414.71M | 464.07M | 542.22M | 593.51M |
Cash Flow | ||||||
| Free Cash Flow | -81.44M | -86.92M | -134.38M | -106.16M | -180.97M | -163.94M |
| Operating Cash Flow | -81.43M | -86.92M | -134.37M | -105.92M | -178.79M | -158.27M |
| Investing Cash Flow | -51.66M | 64.62M | 240.89M | 68.99M | -107.22M | 197.38M |
| Financing Cash Flow | -3.02M | -6.46M | -16.96M | 78.14M | -29.83M | 22.73M |
PureTech Health Technical Analysis
Positive
122.40
Price Trends
116.71
Positive
120.26
Negative
123.49
Negative
Market Momentum
0.40
Negative
55.15
Neutral
77.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PRTC, the sentiment is Positive. The current price of 122.4 is above the 20-day moving average (MA) of 113.33, above the 50-day MA of 116.71, and below the 200-day MA of 123.49, indicating a neutral trend. The MACD of 0.40 indicates Negative momentum. The RSI at 55.15 is Neutral, neither overbought nor oversold. The STOCH value of 77.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:PRTC.
PureTech Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | £82.07M | -4.57 | -316.73% | ― | -56.10% | -16.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £288.33M | 157.43 | 0.14% | ― | -4.11% | -96.92% | |
47 Neutral | £37.37M | 165.00 | 3.75% | ― | ― | ― | |
45 Neutral | £24.33M | -3.12 | -559.87% | 17.86% | ― | 5.62% | |
44 Neutral | £107.89M | -5.09 | 128.87% | ― | -100.00% | -30.39% | |
43 Neutral | £296.94M | -6.69 | -1293.07% | ― | ― | ― |
* Healthcare Sector Average
GB:PRTC
PureTech Health
117.40
-14.60
-11.06%
GB:AVCT
Avacta Group plc
60.50
-9.50
-13.57%
GB:IMM
ImmuPharma
3.25
-8.35
-71.98%
GB:SCLP
Scancell Holdings
87.40
-11.10
-11.27%
GB:4BB
4basebio UK Societas
530.00
-260.00
-32.91%
GB:AREC
Arecor Therapeutics PLC
82.50
11.00
15.38%
PureTech Health Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
PureTech pivots to leaner, capital-light model as portfolio advances and Seaport IPO boosts asset base
Positive
Sep 22, 2026
PureTech Health reported significant half-year progress across its portfolio, highlighted by Seaport Therapeutics’ upsized Nasdaq IPO, Celea Therapeutics’ $180 million financing and initiation of the Phase 3 SURPASS-IPF trial of deupir...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
PureTech’s Gallop Oncology Wins FDA Fast Track for LYT-200 in High-Risk MDS
Positive
Sep 21, 2026
PureTech Health announced that its founded entity Gallop Oncology has completed a successful End-of-Phase 1 meeting with the U.S. Food and Drug Administration for LYT-200 in relapsed or refractory high-risk myelodysplastic syndromes. The company a...
Business Operations and Strategy
PureTech’s Seaport arm posts positive GlyphAllo driving trial data
Positive
Sep 9, 2026
PureTech Health’s founded entity Seaport Therapeutics has reported positive topline data from a Phase 1 driving simulation trial of GlyphAllo, an oral prodrug of allopregnanolone in development for major depressive disorder. The study showed...
Business Operations and StrategyFinancial Disclosures
PureTech Health Sets Date for Half-Year 2026 Results
Neutral
Sep 4, 2026
PureTech Health plc announced that it will release its half-year results for the six months ended 30 June 2026 on Tuesday 22 September 2026. The company will host a presentation and conference call at 9:00 a.m. BST on the same day, with a webcast ...
Business Operations and StrategyRegulatory Filings and Compliance
PureTech updates share capital and voting rights as of August 2026
Neutral
Sep 1, 2026
PureTech Health, a biotherapeutics company using a hub-and-spoke, capital-efficient RD strategy, concentrates on de-risked therapeutic assets addressing significant patient needs and has advanced dozens of candidates, three of which have secured U...
Business Operations and StrategyProduct-Related Announcements
PureTech’s Celea to Spotlight Phase 3 IPF Drug Deupirfenidone at ERS Congress
Positive
Aug 25, 2026
PureTech-founded Celea Therapeutics will showcase its Phase 3 program for deupirfenidone in idiopathic pulmonary fibrosis at the European Respiratory Society Congress in Barcelona, including the design of the SURPASS-IPF global head-to-head trial ...
Business Operations and StrategyExecutive/Board Changes
PureTech Health Issues RSU-Based Shares to Senior Management
Neutral
Aug 18, 2026
PureTech Health plc has issued ordinary shares to senior executives following the vesting of restricted share units granted under its Performance Share Plan, reflecting the company’s ongoing use of equity-based incentives. The awards, which ...
Business Operations and StrategyRegulatory Filings and Compliance
PureTech updates share capital and voting rights as it emphasizes R&D-driven growth
Positive
Aug 3, 2026
PureTech Health reported that as of 31 July 2026 it had issued 257,927,489 ordinary shares, with 13,552,467 held in treasury, resulting in 244,375,022 voting rights. The disclosure helps investors and other shareholders assess when they must repor...
Executive/Board ChangesRegulatory Filings and Compliance
PureTech Health Awards Vested RSUs to Non-Executive Directors, Updates Share Capital
Neutral
Jul 31, 2026
PureTech Health plc has issued new ordinary shares to several non-executive directors following the full vesting of restricted share units granted under its Performance Share Plan in late 2025. The awards, settled on July 29, 2026, provided each o...
Executive/Board ChangesRegulatory Filings and Compliance
PureTech Health Issues Vested RSU Shares to Senior Executives
Neutral
Jul 17, 2026
PureTech Health has issued ordinary shares to senior executives following the vesting of restricted share units granted under its Performance Share Plan, reflecting a scheduled equity-based compensation event for key management. The awards, net of...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
PureTech’s Celea Starts Landmark Phase 3 Head-to-Head IPF Trial
Positive
Jul 13, 2026
Celea Therapeutics has dosed the first patient in SURPASS-IPF, a global, randomized Phase 3 trial that will directly compare its investigational drug deupirfenidone with established therapy pirfenidone over 52 weeks in approximately 1,100 IPF pati...
Other
PureTech Insiders Boost Holdings with Coordinated Share Purchases
Positive
Jul 9, 2026
PureTech Health reported that several senior insiders, including Chief Executive Officer Robert Lyne and Interim Board Chair Sharon Barber-Lui, purchased ordinary shares on the London Stock Exchange. The transactions, conducted on 7-8 July 2026 at...
Business Operations and StrategyPrivate Placements and Financing
PureTech Spins Out Celea with $180 Million to Advance Phase 3 IPF Drug
Positive
Jul 2, 2026
PureTech Health has launched its founded entity Celea Therapeutics as an independent company and helped it secure $180 million in financing from a syndicate of top-tier healthcare investors. The transaction aligns with PureTech’s strategy of...
Business Operations and StrategyPrivate Placements and Financing
PureTech Spins Out Celea in $180m IPF Bet, Sharpening Lean Portfolio Strategy
Positive
Jul 2, 2026
PureTech Health has launched Celea Therapeutics as an independent, investor-backed entity to advance deupirfenidone, a next-generation antifibrotic aimed at idiopathic pulmonary fibrosis. The new structure reflects PureTech’s shift toward a ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.